Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer

Tanya B. Dorff, David I. Quinn, Cathy M. Tangen, E. David Crawford, Daniel P. Petrylak, Celestia S. Higano, Derek Raghavan, Nicholas J. Vogelzang, Ian M. Thompson

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

The major goals of the Southwest oncology genitourinary (SWOG-GU) committee in the area of advanced prostate cancer are to improve the survival and quality of life (QOL) of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.

Original languageEnglish (US)
Pages (from-to)69-77
Number of pages9
JournalTherapeutic Advances in Medical Oncology
Volume1
Issue number2
DOIs
StatePublished - Sep 2009

    Fingerprint

Keywords

  • advanced prostate cancer
  • androgen deprivation
  • chemotherapy
  • clinical trials

ASJC Scopus subject areas

  • Oncology

Cite this

Dorff, T. B., Quinn, D. I., Tangen, C. M., Crawford, E. D., Petrylak, D. P., Higano, C. S., Raghavan, D., Vogelzang, N. J., & Thompson, I. M. (2009). Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer. Therapeutic Advances in Medical Oncology, 1(2), 69-77. https://doi.org/10.1177/1758834009343454